Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease

a technology of phosphodiesterase 4 and reductase inhibitor, which is applied in the direction of cardiovascular disorders, drug compositions, peptide/protein ingredients, etc., can solve the problems of single mediator or cell type targeting that has not led to satisfactory results, and the success rate of instances limited

Inactive Publication Date: 2010-03-18
TAKEDA GMBH
View PDF22 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, in medical practice for the treatment of e.g. asthma and COPD the targeting of a single mediator or cell type has not lead to satisf

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease
  • Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease
  • Combination of HMG-COA Reductase Inhibitors with Phosphodiesterase 4 Inhibitors for the Treatment of Inflammatory Pulmonary Disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0009]It has now been found that the combined use of a PDE4 inhibitor and a HMG-CoA reductase inhibitor potentiates the anti-inflammatory effect of either component alone.

[0010]Therefore, according to a first aspect of the present invention there is provided a pharmaceutical composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof, an amount of a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease, and at least one pharmaceutically acceptable auxiliary.

[0011]The above-mentioned pharmaceutical composition provides for the administration of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof with a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof and is thus presented as a single formula...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Login to view more

Abstract

The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease.

Description

TECHNICAL FIELD[0001]The present invention relates to the combination of certain known therapeutic compounds for therapeutic purposes. The substances used in the combinations according to the invention are known active agents from the phosphodiesterase 4 (PDE4) inhibitor class and active agents from the HMG-CoA-reductase inhibitor class.BACKGROUND ART[0002]Statins are widely used as cholesterol lowering therapeutic agents. They reduce cholesterol levels through competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the key enzyme that regulates cholesterol synthesis. The cholesterol-lowering effect of statins is also due to an increase in the uptake of cholesterol by cells as a result of intracellular cholesterol depletion and enhanced expression of low-density lipoprotein (LDL) receptors.[0003]However, statins exhibit properties that are beyond their lipid-lowering effects. These non-lipid-lowering properties involve the inhibition of the isoprenoid pa...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/502A61K31/437A61K31/4439A61K31/44A61K31/40A61K31/366A61K31/343A61K31/215A61K31/192A61P11/04A61P29/00A61P11/00
CPCA61K31/22A61K31/277A61K45/06A61K31/505A61K31/502A61K31/453A61K31/343A61K31/352A61K31/366A61K31/40A61K31/405A61K31/437A61K31/44A61K31/4439A61K2300/00A61P11/00A61K31/4425A61P11/04A61P11/06A61P29/00A61P35/00A61P43/00A61P9/12
Inventor WOLLIN, STEFAN-LUTZ
Owner TAKEDA GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap